Bide Pharmatech (SH:688073) Shang Hai Zheng Quan Bao·2025-08-21 18:53Group 1 - The company reported a total fundraising amount of RMB 1,428,160,800 from its initial public offering, with a net amount of RMB 1,308,998,865 after deducting various fees [4][21][30] - As of June 30, 2025, the remaining balance of the raised funds, including interest income, was RMB 85,306,200, with specific amounts allocated to different bank accounts [6][20] - The company has established a dedicated fund management system, including signing tripartite supervision agreements with banks and underwriters to ensure proper use of the raised funds [6][20] Group 2 - The company has utilized part of the raised funds to replace self-funded expenditures for investment projects, amounting to RMB 122,087,800 [7][24] - The company has also approved the use of excess raised funds, totaling RMB 260,000,000, for repaying bank loans and supplementing working capital, ensuring that this does not affect the investment projects [9][28] - The company has conducted a comprehensive assessment of its assets and recognized impairment losses totaling RMB 21,917,000 for the first half of 2025, reflecting a cautious approach to financial reporting [31][33] Group 3 - The company has made adjustments to its fundraising investment projects, extending the implementation timeline and reallocating certain budget items without affecting the overall project scope [11][12] - The company has confirmed that all used raised funds have been directed towards the promised investment projects, with no violations in fund usage [15][24] - The company has undergone a governance structure adjustment, electing new members to its board committees to enhance operational efficiency [18][19]